Clinical Trials

Product Surveillance Registry Platform
Evaluate the periodic reporting of safety and effectiveness of Medtronic market-released products for their intended use.
Principal Investigator: Sankar Varanasi, MD

Librexia AF
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.
Principal Investigators: M. Zubair Jafar, MD / Carol Gemayel-Barra, MD

Real AF
Real-world Experience of Catheter Ablation for the Treatment of Symptomatic ParoxysmaL and Persistent Atrial Fibrillation Using Novel CARTO Technologies
Principal Investigator: David Steckman, MD

Preference Survey Study
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
Principal Investigators: M. Zubair Jafar, MD / Carol Gemayel-Barra, MD 

Venclose
Study using the Venclose™ System and Venclose MAVEN™ System for Treatment of Chronic Venous Insufficiency of the Great and Small Saphenous Veins and Incompetent Perforator Veins
Principal Investigator: Louis Kantaros, MD

Victorian-1 Prevent
A Randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients
Principal Investigator: Sunny Intwala, MD

DAL-302 (dal-GenE-2)
A phase 3, double-blind, randomized placebo-controlleed study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in genetically defined population with a recent Acute Coronary Syndrome (ACS)
Principal Investigator: Rajeev Narayan, MD

ALLEVIATE
Algorithm using LINQ Sensors for Evaluation and Treatment of Heart Failure (ALLEVIATE-HF)

Principal Investigator: Sankar Varanasi, MD

DAPA ACT HF/TIMI 68

This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
Principal Investigator: James Lyons, MD

EMPOWER (FKA CARILLON)
The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).
Principal Investigator: Rajeev Narayan, MD

Drain HF
Diuretics Alone vs Aortix Endovascular Device for Acute Heart Failure
Principal Investigators: James Lyons, MD / Rajeev Narayan, MD

AIM HIGHer
Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction- Heart Failure
Principal Investigator: James Lyons, MD

BalanceD-HF
A Phase III, Randomized, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function
Principal Investigator: James Lyons, MD

Contemp-ICD
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy in Contemporary Heart Failure Patients with a Low Risk for Arrhythmic Death
Principal Investigator: Sankar Varanasi, MD

TPOXX-EAP
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children
Principal Investigators: Valerie Cluzet, MD / Paul Nee, MD / Paolo Pino, DO

Enlight-LN
A Prospective Observational Registry of Patients Treated with LUPKYNIS (voclosporin) in the US
Principal Investigator: Alla Rudinskaya, MD

Evolve MI 
A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
Principal Investigator: Louis Kantaros, MD

Artemis
Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction
Principal Investigator: Hal Wasserman, MD

Vesalius CV
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infactrion or Stroke
Principal Investigator: Louis Kantaros, MD

Aspire
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)
Principal Investigator: Paul Wright, MD

Oceanic Stroke
A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor Asundexian (BAY 2433334) for the secondary prevention of ischemic stroke in adult patients with an acute non-cardioembolic ischemic stroke or high-risk TIA 
Principal Investigator: Paul Wright, MD

ReVive
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy.

Principal Investigator: Paul Wright, MD

MYRIAD REGISTRY
Registry of Myriad Utilization in Soft Tissue Reconstruction Procedures
Principal Investigators: John Choi, MD / Pranat Kumar, MD